Epstein J I
Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Oncology (Williston Park). 1996 Apr;10(4):527-34; discussion 539, 541-3.
During the last few years, pathologists have assumed several important roles in the assessment of adenocarcinomas of the prostate. The establishment of postoperative serum prostate-specific antigen (PSA) levels as a sensitive indicator of progression following radical prostatectomy has provided the impetus to correlate pathologic findings with progression following surgery. The advent of the thin needle biopsy gun and screening with serum PSA has dramatically increased the number of needle biopsies performed to rule out prostatic adenocarcinoma. With these very limited tissue samples, pathologists are challenged to make diagnoses, as well as to accurately grade and quantify the tumor. This article explores topical issues in the pathology of prostate adenocarcinoma, with particular emphasis on practical aspects of pathologic evaluation that oncologists need to know for patient management.
在过去几年中，病理学家在前列腺腺癌的评估中承担了几个重要角色。术后血清前列腺特异性抗原（PSA）水平作为根治性前列腺切除术后疾病进展的敏感指标的确立，推动了将病理结果与术后疾病进展相关联的研究。细针活检枪的出现以及血清PSA筛查显著增加了为排除前列腺腺癌而进行的针吸活检数量。面对这些非常有限的组织样本，病理学家在做出诊断以及准确分级和量化肿瘤方面面临挑战。本文探讨前列腺腺癌病理学中的热点问题，特别强调肿瘤学家在患者管理中需要了解的病理评估实际方面。
